Lifecore Biomedical Inc.
Thesis
Lifecore is poised for significant growth as it expands its manufacturing capacity in a market that is short on fill/finish CDMO capacity. With revenues, profits, and customer pipeline at record highs, the company is expected to fill its new capacity with high-margin production, leading to rapid profit growth and a substantial increase in share price. Lifecore currently trades at $6 per share, but could reach $20-30 per share as new customers are onboarded and commercial production ramps up.
Did it work?
The thesis called for a substantial share price increase (from $6 toward $20-30) driven by rapid, high-margin profit growth as new capacity filled. Instead, 28 months later the stock is down 24.3%, moving decisively against the long thesis rather than merely lagging an implied multi-year ramp. While the operational claims (record revenues, pipeline) cannot be verified from the data given, the core investment expectation of significant appreciation has clearly not materialized and the price action contradicts it.